Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral sirolimus for pediatric PIK3CA-Related Overgrowth Spectrum (complex vascular malformations)
ChiCTR2200056185Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sirolimus in PIK3CA-related overgrowth spectrum (PROS) and vascular malformation, sponsored by Beijing Children's Hospital. Primary endpoint: Effective rate. Started Jun 2022; status: recruiting.
02
Drugs
sirolimus
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)vascular malformation
Beyond the preview
Go deeper on ChiCTR2200056185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056185.